s100a8 9  (R&D Systems)

Journal: JID Innovations

Article Title: A neuroimmune axis linking S100A8/9 to itch sensitization in both bullous pemphigoid and atopic dermatitis

doi: 10.1016/j.xjidi.2026.100470

Figure Lengend Snippet: Increased S100A8/9 expression in the skin and serum of patients with BP and AD. ( a ) Immunohistochemical analysis with anti-S100A8/9 antibody showing the expression of S100A8/9 in keratinocytes and infiltrating inflammatory cells of lesional skin of patients with BP and AD. S100A8/9 expression was not observed in the healthy skin. Scale bar: 100 μm. (b) Quantification of the expression level of S100A8/9. (control, n = 2; BP, n = 5; AD n = 2). Inter-patient heterogeneity of the expression level of S100A8/9 was observed in the BP skin samples, and representative images of both low and high S100A8/9 expression were shown in A. (c) ELISA analysis showing increased S100A8/9 concentrations in the serum of patients with BP. (control, n = 8; BP, n = 16; P = .0087, Mann-Whitney test). Data are reported as mean ± SD. AD, atopic dermatitis; BP, bullous pemphigoid.

Article Snippet: Chemicals used are listed as follows: S100A8, S100A9, and S100A8/9 (100 ng/ml, R&D Systems, 9877-S8, 2065-S9, 8916-S8), Bam8-22 (1 μM, custom synthesized by Genscript), and capsaicin (Sigma M2028, 1 μM).

Techniques: Expressing, Immunohistochemical staining, Control, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY

Journal: JID Innovations

Article Title: A neuroimmune axis linking S100A8/9 to itch sensitization in both bullous pemphigoid and atopic dermatitis

doi: 10.1016/j.xjidi.2026.100470

Figure Lengend Snippet: S100A8/9 directly activates small-diameter, nociceptive DRG sensory neurons. ( a ) Representative fluorescent images of cultured DRG sensory neurons isolated from Pirt GCaMP3/+ mice before and after S100A8/9 (100 ng/ml) application. Arrows point to sensory neurons showing increased GCaMP3 fluorescence levels after S100A8/9 application. (b) Histogram showing size distribution of S100A8/9-responsive neurons. (c–e) Representative traces of DRG neurons evoked by indicated chemicals, including S100A8/9 (100 ng/ml), S100A8 (100 ng/ml), S100A9 (100 ng/ml), capsaicin (1 μM), and KCl (75 mM) in a calcium imaging assay. All S100A8/9-sensitive neurons responded to capsaicin and KCl. The majority of S100A8- and S100A9-responsive neurons also responded to S100A8/9. The three different colors (Red, Green, and Blue) represent individual cells in C-E. (f) TAK-242 inhibited S100A8/9-induced calcium responses in sensory neurons. (n = 3 for both groups P = .018, Welch’s t -test). Data are reported as mean ± SD. AD, atopic dermatitis; BP, bullous pemphigoid; DRG, dorsal root ganglia.

Article Snippet: Chemicals used are listed as follows: S100A8, S100A9, and S100A8/9 (100 ng/ml, R&D Systems, 9877-S8, 2065-S9, 8916-S8), Bam8-22 (1 μM, custom synthesized by Genscript), and capsaicin (Sigma M2028, 1 μM).

Techniques: Cell Culture, Isolation, Fluorescence, Imaging

Journal: JID Innovations

Article Title: A neuroimmune axis linking S100A8/9 to itch sensitization in both bullous pemphigoid and atopic dermatitis

doi: 10.1016/j.xjidi.2026.100470

Figure Lengend Snippet: S100A8/9 potentiate histamine-induced itch. ( a ) Subcutaneous injection of S100A8/9 (20 μg/ml) into the nape of the neck of wild-type mice does not induce scratching behavior. (n = 7 for both groups, P = .97, Welch’s t test). (b) Co-injection of S100A8/9 increased histamine (20 mM)-induced scratching behavior. (n = 11 for both groups, P = .038, Welch’s t test). Data are reported as mean ± SD.

Article Snippet: Chemicals used are listed as follows: S100A8, S100A9, and S100A8/9 (100 ng/ml, R&D Systems, 9877-S8, 2065-S9, 8916-S8), Bam8-22 (1 μM, custom synthesized by Genscript), and capsaicin (Sigma M2028, 1 μM).

Techniques: Injection

Journal: Biomolecules

Article Title: Evaluation of Plasma-Derived hsa_circ_003077 for Non-Invasive Diagnosis of Alzheimer’s Disease

doi: 10.3390/biom16030356

Figure Lengend Snippet: Plasma glial and receptor biomarkers in Alzheimer’s disease (AD) patients and cognitively healthy controls (HC). ( a ) GFAP, ( b ) NfL, ( c ) Tyro3, and ( d ) AXL levels were measured in plasma. Data are presented as mean ± SEM. Statistical comparisons were performed using the Mann–Whitney U test. Statistical significance is indicated as ** p < 0.01; *** p < 0.001; ns, not significant.

Article Snippet: The Human Tyro3 DuoSet ELISA kit (Catalog No: DY8596-05) supplied by R&D Systems (Minneapolis, MN, USA) was used to measure Tyro3 levels, while the Human AXL DuoSet ELISA kit (Catalog No: DAXL00; R&D Systems, Minneapolis, MN, USA) was used to measure AXL levels.

Techniques: Clinical Proteomics, MANN-WHITNEY

Journal: Biomolecules

Article Title: Evaluation of Plasma-Derived hsa_circ_003077 for Non-Invasive Diagnosis of Alzheimer’s Disease

doi: 10.3390/biom16030356

Figure Lengend Snippet: Diagnostic performance of plasma biomarkers for differentiating Alzheimer’s disease (AD) from cognitively healthy controls (HC) based on ROC curve analysis. Receiver operating characteristic (ROC) curves were generated to assess the diagnostic accuracy of plasma biomarkers. The area under the ROC curve (AUC) was used to evaluate biomarker performance: 0.90–1.00, superior diagnostic efficacy; 0.80–0.89, good diagnostic efficacy; 0.70–0.79, moderate diagnostic efficacy; <0.70, poor/substandard diagnostic efficacy. Data are presented as mean ± SEM. Statistical comparisons were performed using the Mann–Whitney U test. hsa_circ_003077 exhibited the highest diagnostic accuracy (AUC = 0.90; 95% CI: 0.82–0.97), followed by NfL (AUC = 0.75) and pTau-217 (AUC = 0.77). AXL and GFAP showed lower diagnostic performance (AUC = 0.63 and 0.69, respectively), while pTau-181 and Tyro3 demonstrated substandard efficacy (AUC = 0.63 each).

Article Snippet: The Human Tyro3 DuoSet ELISA kit (Catalog No: DY8596-05) supplied by R&D Systems (Minneapolis, MN, USA) was used to measure Tyro3 levels, while the Human AXL DuoSet ELISA kit (Catalog No: DAXL00; R&D Systems, Minneapolis, MN, USA) was used to measure AXL levels.

Techniques: Diagnostic Assay, Clinical Proteomics, Generated, Biomarker Discovery, MANN-WHITNEY